Trending
- 1 FUNCTIONAL NEUROMODULATION: Announces Breakthrough Device Designation from the U.S. FDA for Deep Brain Stimulation for Alzheimer's Disease
- 2 BAYER: U.S. FDA Approves Addition of Overall Survival and Other Secondary Endpoint Data to NUBEQA® (darolutamide) Prescribing Information
Newsletter
Get the latest business news and updates - delivered right to your inbox
By signing up you agree to receive email newsletters or alerts from FDA Reporter. You can unsubscribe at any time.